AstraZeneca beats Q3 forecasts and launches a $1.5bn savings programme to fund its pipeline
The Anglo-Swedish drugmaker kept its 2026 guidance and said the savings will be reinvested, mainly in more than 180 pipeline projects. It gave few details on where the cuts will fall.
AstraZeneca reported third-quarter 2026 total revenue of $16,209 million on Friday 30 October, up 7% at constant exchange rates. Core earnings per share rose 19% at constant rates to $2.79. Both beat analysts' forecasts of $15.94 billion and $2.59, according to Reuters, and the company reconfirmed its 2026 guidance.
Alongside the results, the Cambridge, UK-based group launched a programme called Reshaping for Sustainable Growth. It expects up to $2.0 billion in one-time restructuring costs and about $1.5 billion in annualised pre-tax savings, to be reinvested mainly in its pipeline.
The quarter
Product sales were $15,066 million and alliance revenue $1,107 million in the quarter, according to the results release. Reported earnings per share were $2.02. For the first nine months, total revenue was $46,881 million, up 7% at constant exchange rates, and core earnings per share were $8.00, up 14%.
Oncology drove growth. Reuters reported that cancer revenue rose 17% to $7.77 billion, with Enhertu sales up 35% to $969 million and Imfinzi up 26% to about $2 billion. That offset older products facing generic competition: sales of the diabetes drug Farxiga fell 25% to $1.61 billion. The company also cited loss of exclusivity for Brilinta and volume-based procurement in China as headwinds.
Pre-tax profit rose 22% to $3.96 billion and operating profit by 22% to $4.39 billion, The Independent reported. Shares rose about 3% in morning trading, according to Reuters.
The savings programme
AstraZeneca says it is in a catalyst-rich period with more than 180 pipeline projects. The new programme will, over three years, redeploy resources and strengthen capabilities across its existing business and therapy areas. Activities should be essentially complete by the end of 2029.
The company did not say where the savings would come from or whether jobs would be cut, both Reuters and The Independent noted. Reuters calculated that the $1.5 billion equals roughly 4% of AstraZeneca's 2025 operating expenses of $34.36 billion. Operating expenses in the first nine months of 2026 were $27.56 billion, up 7%, and the company said costs would rise again in the fourth quarter in line with seasonal trends. British rival GSK is also running a cost programme.
The 2030 target
Chief executive Pascal Soriot is trying to show investors that AstraZeneca can reach $80 billion in annual revenue by 2030, a target that relies partly on about 20 new drug launches. "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade," he said. The company said it has received 47 approvals in major regions since its Q4 2025 results, including first approvals for four new medicines.
Questions about the pipeline have grown after setbacks involving camizestrant and Wainua, according to Reuters. Analysts are now looking to 2027, when AstraZeneca expects late-stage trial results that it says could support more than $20 billion in peak annual sales. In October it also opened a new global R&D centre in Kendall Square, Cambridge, Massachusetts, for nearly 2,000 researchers. Full-year results are due on 9 February 2027.
What it means for founders and investors
Big pharma cost programmes rarely mean less spending on science. AstraZeneca says the savings will be reinvested principally in the pipeline, which in practice means late-stage trials, new modalities and technology. For European biotech founders, that keeps one of the region's largest buyers of drug candidates and research partnerships active, even while it tightens costs elsewhere.
The results also fit a pattern this week. Sanofi raised its guidance and said it was open to larger deals, while Recordati's takeover showed private equity appetite for European pharma. Startups working on AI for clinical development, such as Atlas Bio, and drug discovery companies like ALLOX sit right where large drugmakers say they want more productivity.
The open question is how the restructuring lands inside AstraZeneca's European sites, including Cambridge in the UK and Gothenburg in Sweden. The company has not said, and investors will look for more detail with the full-year results in February.
Spotted an error? Email contact@europreneursmedia.com and we'll correct it. See our corrections policy and editorial standards.
